#1 Clinical Trials Search in Europe

Mps-216

This article explores clinical trials investigating the use of MPS-216, a component of the cancer vaccine OSE2101 (Tedopi), in various cancer types. OSE2101 is being studied as an immunotherapy approach for treating advanced cancers, particularly non-small cell lung cancer (NSCLC), ovarian cancer, and pancreatic cancer. The trials aim to evaluate the safety and efficacy of OSE2101 alone or in combination with other treatments.

Table of Contents

What is MPS-216?

MPS-216 is one of the active substances in TEDOPI, a cancer vaccine being developed by OSE Immunotherapeutics[1]. TEDOPI is an emulsion for injection that contains 10 synthetically manufactured peptides, including MPS-216[2]. A peptide is a short chain of amino acids, which are the building blocks of proteins. In the case of TEDOPI, these peptides are designed to stimulate the immune system to fight cancer cells.

How Does MPS-216 Work?

As part of the TEDOPI vaccine, MPS-216 works by stimulating the immune system to recognize and attack cancer cells. The vaccine is designed for patients with a specific genetic marker called HLA-A2, which is present in about 45% of the population[1]. When injected, the peptides in TEDOPI, including MPS-216, are recognized by the immune system as foreign substances. This triggers an immune response specifically targeted against cancer cells that express these peptides.

What Conditions is MPS-216 Being Studied For?

MPS-216, as a component of TEDOPI, is being studied for several types of cancer:

  • Non-Small Cell Lung Cancer (NSCLC): TEDOPI is being investigated for patients with advanced or metastatic NSCLC who have failed previous treatments[1].
  • Ovarian Cancer: A study is looking at TEDOPI as a maintenance treatment for patients with platinum-sensitive recurrent ovarian cancer[3].
  • Pancreatic Cancer: TEDOPI is being studied in combination with chemotherapy for patients with locally advanced or metastatic pancreatic ductal adenocarcinoma[4].

Clinical Trials Involving MPS-216

Several clinical trials are currently underway to evaluate the effectiveness and safety of TEDOPI, which includes MPS-216:

  • ARTEMIA Study: This is a phase 3 trial comparing TEDOPI to docetaxel in patients with advanced NSCLC who have developed resistance to immune checkpoint inhibitors[1].
  • TEDOVA Study: A phase 2 trial evaluating TEDOPI alone or in combination with pembrolizumab as a maintenance treatment for ovarian cancer[3].
  • TEDOPAM Study: A phase 2 trial studying TEDOPI in combination with chemotherapy for pancreatic cancer[4].

Potential Benefits and Side Effects

The potential benefits of TEDOPI, including MPS-216, are its ability to stimulate the immune system to fight cancer cells. This approach, known as immunotherapy, has shown promise in treating various types of cancer.

As for side effects, the full safety profile of TEDOPI is still being studied in clinical trials. Common side effects of cancer vaccines may include injection site reactions, flu-like symptoms, and fatigue. More serious side effects can occur but are generally rare. It’s important to note that the safety and efficacy of TEDOPI are still being evaluated in clinical trials[2][1][3].

Current Status and Future Directions

TEDOPI, including MPS-216, is still considered an investigational drug. It is not yet approved for general use and is only available through clinical trials. The ongoing studies will help determine its effectiveness and safety in treating various types of cancer.

If the results from these trials are positive, TEDOPI could potentially become a new treatment option for patients with certain types of cancer, particularly those who have not responded well to other treatments[1][3][4].

Trial Name Cancer Type Phase Treatment Primary Endpoint
ARTEMIA Metastatic NSCLC III OSE2101 vs. docetaxel Overall Survival
Unnamed Advanced solid tumors, lymphomas, NSCLC I/II OSE-279 +/- OSE2101 Safety, MTD, RP2D, ORR
TEDOVA Recurrent ovarian cancer II OSE2101 +/- pembrolizumab vs. best supportive care Progression-Free Survival
TEDOPAM Advanced pancreatic cancer II OSE2101 + FOLFIRI vs. FOLFIRI alone Overall Survival at 12 months

FAQ

  • What is MPS-216? MPS-216 is one of the active substances in OSE2101 (Tedopi), which is an experimental cancer vaccine being studied in clinical trials. It is part of a combination of synthetic peptides designed to stimulate the immune system to target cancer cells.
  • What types of cancer are being studied with MPS-216? Clinical trials are investigating the use of MPS-216 (as part of OSE2101) in non-small cell lung cancer (NSCLC), ovarian cancer, and pancreatic cancer. These trials focus on patients with advanced or metastatic disease.
  • How is OSE2101 administered? OSE2101 is administered as an emulsion for injection, typically given subcutaneously (under the skin). The exact dosing schedule may vary depending on the specific clinical trial protocol.
  • What are the main goals of these clinical trials? The main goals of these trials are to assess the safety and efficacy of OSE2101. This includes evaluating overall survival, progression-free survival, objective response rates, and quality of life in patients treated with the vaccine alone or in combination with other therapies.
  • Who is eligible to participate in these clinical trials? Eligibility criteria vary by trial but generally include adult patients with specific cancer types, HLA-A2 positive status, adequate organ function, and no recent use of certain other cancer treatments. Patients must also be willing and able to comply with study procedures.

Ongoing Clinical Trials on Mps-216

  • Study on Cemiplimab and OSE2101 for Maintenance Therapy in Patients with ctDNA Positive Non-Small Cell Lung Cancer (NSCLC)

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Tedopi and Nivolumab for Patients with Advanced Non-Small Cell Lung Cancer After Initial Treatment

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

  • Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium France Germany Greece Hungary Italy +5

  • Study of OSE-279 and OSE2101 Drug Combination for Patients with Advanced Solid Tumors, Lymphomas, or Metastatic Non-Small Cell Lung Cancer

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Spain

  • Study on Maintenance Therapy with OSE2101 and FOLFIRI for Patients with Advanced Pancreatic Cancer After Initial FOLFIRINOX Treatment

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of OSE2101 vaccine alone or with pembrolizumab as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer after chemotherapy

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany

Glossary

  • HLA-A2: Human Leukocyte Antigen-A2, a specific protein found on the surface of cells. Patients must be HLA-A2 positive to be eligible for treatment with OSE2101 in these trials.
  • NSCLC: Non-Small Cell Lung Cancer, a type of lung cancer that is the focus of several trials using OSE2101.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Immunotherapy: A type of cancer treatment that helps the immune system fight cancer.
  • ECOG Performance Status: A scale used to assess how a patient's disease affects their daily living abilities and determine appropriate treatment and prognosis.
  • Adverse Events (AEs): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.

References

  1. http://clinicaltrials.eu/trial/study-comparing-ose2101-and-docetaxel-for-patients-with-metastatic-non-small-cell-lung-cancer-after-immunotherapy-resistance/
  2. http://clinicaltrials.eu/trial/study-of-ose-279-and-ose2101-drug-combination-for-patients-with-advanced-solid-tumors-lymphomas-or-metastatic-non-small-cell-lung-cancer/
  3. http://clinicaltrials.eu/trial/study-of-maintenance-treatments-with-ose2101-and-pembrolizumab-for-patients-with-recurrent-ovarian-cancer-after-platinum-based-chemotherapy/
  4. http://clinicaltrials.eu/trial/study-on-maintenance-therapy-with-ose2101-and-folfiri-for-patients-with-advanced-pancreatic-cancer-after-initial-folfirinox-treatment/